Non-adherence to Psychotropic Medication Among Adolescents – A                     Systematic Review of the Literature

Häge, Alexander; Weymann, Lisa; Bliznak, Lucia; Märker, Viktoria; Mechler, Konstantin; Dittmann, Ralf W.

doi:10.1024/1422-4917/a000505

Cited by 40 publications

(29 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another line of interest was stimulated by clinical questions as well, both from paediatrics and CAP, namely, Coping, Compliance, and (Medication) Non-/Adherence, a topic then covered repeatedly over decades [17][18][19][20][21][22].…”

Section: -1987: Specialist Training and First Steps In Cap Researchmentioning

confidence: 99%

See 1 more Smart Citation

Child & Adolescent Psychiatry in Development - A Personal Retrospective Account Across Five Decades

Dittmann¹

2019

Int J Psychiatr Res

Self Cite

View full text Add to dashboard Cite

This personal account covers first steps and the individual development of the author within the-then in Germany newly established-field of ,child and adolescent psychiatry (CAP)', across a five-decade period, both in national and international environments, in clinical, academic, and pharmaceutical industry settings. Early years in medical school, practical experience, and psychology studies, succeeded by theses and examinations, were all directed to successfully gain adequate knowledge/skills to become a well-trained CAP clinician. Specialist residencies followed, in CAP/psychosomatics, paediatrics and adult psychiatry. In parallel to broad clinical responsibilities, soon, first research activities, successful grant applications, and intensive collaborations with publicly funded research consortia were strongly stimulated, to start an academic career. Clinical research in CAP areas of, e.g., psychoendocrinology/intersexuality, psychophysiology, psychopharmacology, migrant psychiatry, coping and compliance in somatic disease were pursued, including a 2-year research assignment abroad (USA). Unexpectedly, back in Germany, the author joined clinical CNS research in an international pharmaceutical company for several years, finally focussing on studies in juveniles. Over the last decade of his professional life, he became endowed chair, professor and director of a research group for ‚paediatric psychopharmacology' in a university department, the first of its kind in Europe. Currently open questions and challenges in this field conclude the report.

show abstract

Section: -1987: Specialist Training and First Steps In Cap Researchmentioning

confidence: 99%

“…Since 2012, an ongoing non-funded research program (SEMA, [22,38] of the RG has focussed on the inadequately investigated topic of, medication (non-)adherence; this work was awarded the AGNP (German equivalent to ECNP/CINP) prize 2018 for psychopharmacology [39].…”

Section: -2018: Back To University Cap and Academiamentioning

confidence: 99%

Child & Adolescent Psychiatry in Development - A Personal Retrospective Account Across Five Decades

Dittmann¹

2019

Int J Psychiatr Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Adherence to antipsychotic medication is poor in FEP; around 60% of them have either non-adherence or poor adherence (Whale, Harris, Kavanagh, et al, 2016). Further implications of maintenance treatment include metabolic disturbances which lead to increased risks for cardiovascular disease and diabetes and the potential for a 20 to 30 year reduction in life expectancy in people with psychosis (De Hert et al, 2011), accounts for the majority of this mortality (Hage et al, 2018).…”

Section: The Impact Of Antipsychotic Maintenance Treatmentmentioning

confidence: 99%

“…Further implications of maintenance treatment include metabolic disturbances which lead to increased risks for cardiovascular disease and diabetes and the potential for a 20 to 30 year reduction in life expectancy in people with psychosis (De Hert et al, ; Olfson, Gerhard, Huang, Crystal, & Stroup, ; Subotnik, Nuechterlein, Ventura, & Marder, ). Metabolic and cardiovascular illness, in large part due to antipsychotic medication (De Hert et al, ), accounts for the majority of this mortality (Hage et al, ).…”

Section: Introductionmentioning

confidence: 99%

Can antipsychotic dose reduction lead to better functional recovery in first‐episode psychosis? A randomized controlled‐trial of antipsychotic dose reduction. The reduce trial: Study protocol

Weller

Gleeson

Álvarez‐Jiménez

et al. 2018

Early Intervention Psych

View full text Add to dashboard Cite

Antipsychotic medication has been the mainstay of treatment for psychotic illnesses for over 60 years. This has been associated with improvements in positive psychotic symptoms and a reduction in relapse rates. However, there has been little improvement in functional outcomes for people with psychosis. At the same time there is increasing evidence that medications contribute to life shortening metabolic and cardiovascular illnesses. There is also uncertainty as to the role played by antipsychotic medication in brain volume changes. Aim The primary aim of the study is, in a population of young people with first‐episode psychosis, to compare functional outcomes between an antipsychotic dose reduction strategy with evidence‐based intensive recovery treatment (EBIRT) group (DRS+) and an antipsychotic maintenance treatment with EBIRT group (AMTx+) at 24‐months follow‐up. Methods Our single‐blind randomized controlled trial, within a specialist early psychosis treatment setting, will test the whether the DRS+ group leads to better vocational and social recovery than, the AMTx+ group over a 2‐year period in 180 remitted first‐episode psychosis patients. Additionally, we will examine the effect of DRS+ vs AMTx+ on physical health, brain volume and cognitive functioning. This study will also determine whether the group receiving DRS+ will be no worse off in terms of psychotic relapses over 2 years follow‐up. Results This paper presents the protocol, rationale and hypotheses for this study which commenced recruitment in July 2017. Conclusion This study will provide evidence as to whether an antipsychotic dose‐reduction recovery treatment leads to improved functioning and safer outcomes in first‐episode psychosis patients. In addition, it will be the first‐controlled experiment of the effect of exposure to antipsychotic maintenance treatment on brain volume changes in this population.

show abstract

“…Poor medication adherence can be one cause of non-response to a medication. 10 Antidepressant non-adherence is common among children with depression 11,12 and in adults with anxiety disorders. 13-15 However, research specifically on SSRI adherence in children with anxiety disorders is lacking.…”

Section: Introductionmentioning

confidence: 99%

Examining Parental Medication Adherence as a Predictor of Child Medication Adherence in Pediatric Anxiety Disorders

et al. 2018

View full text Add to dashboard Cite

show abstract

Non-adherence to Psychotropic Medication Among Adolescents – A Systematic Review of the Literature

Cited by 40 publications

References 33 publications

Child & Adolescent Psychiatry in Development - A Personal Retrospective Account Across Five Decades

Child & Adolescent Psychiatry in Development - A Personal Retrospective Account Across Five Decades

Can antipsychotic dose reduction lead to better functional recovery in first‐episode psychosis? A randomized controlled‐trial of antipsychotic dose reduction. The reduce trial: Study protocol

Examining Parental Medication Adherence as a Predictor of Child Medication Adherence in Pediatric Anxiety Disorders

Contact Info

Product

Resources

About